Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors

Phase 3

Conditions: Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Ovarian Cancer

First Posted Date: 2006-01-11

Last Posted Date: 2013-09-17

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 105

Registration Number: NCT00274950

Locations: 🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom

and more 16 locations

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2006-01-11

Last Posted Date: 2011-02-11

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 40

Registration Number: NCT00274807

Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Biological: filgrastim
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: carboplatin
Drug: prednisone
Drug: etoposide
Drug: vincristine
Drug: ifosfamide

First Posted Date: 2006-01-11

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 100

Registration Number: NCT00274924

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸
Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States

and more 99 locations

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: busulfan
Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2005-12-15

Last Posted Date: 2013-11-20

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT00265889

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

HD12 for Advanced Stages

Phase 3

Completed

Conditions: Hodgkin´s Lymphoma

First Posted Date: 2005-12-13

Last Posted Date: 2012-06-25

Lead Sponsor: University of Cologne

Registration Number: NCT00265031

HD11 for Intermediate Stages

Phase 3

Completed

Conditions: Hodgkin´s Lymphoma

Interventions: Drug: Adriamycin
Drug: Bleomycin
Drug: Vinblastine
Drug: Etoposide
Drug: DTIC
Drug: Procarbazine
Radiation: radiation therapy
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2005-12-13

Last Posted Date: 2011-08-04

Lead Sponsor: University of Cologne

Target Recruit Count: 1395

Registration Number: NCT00264953

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: carboplatin
Drug: etoposide
Drug: ifosfamide

First Posted Date: 2005-11-21

Last Posted Date: 2016-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 98

Registration Number: NCT00255723

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Not Applicable

Terminated

Conditions: Myelodysplastic/Myeloproliferative Diseases
Lymphoma
Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Sarcoma
Chronic Myeloproliferative Disorders
Graft Versus Host Disease

First Posted Date: 2005-11-15

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 4

Registration Number: NCT00253552

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Biological: Filgrastim
Drug: Carboplatin
Drug: Etoposide
Drug: Melphalan
Procedure: Peripheral blood stem cell infusion
Radiation: 131I-MIBG
Radiation: Radiation therapy

First Posted Date: 2005-11-15

Last Posted Date: 2023-04-10

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 50

Registration Number: NCT00253435

Locations: 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of Chicago Comer Children's Hospital, Chicago, Illinois, United States

and more 12 locations

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Phase 2

Terminated

Conditions: Non-Hodgkin's Lymphoma
Cancer

Interventions: Drug: Vincristine
Drug: VP-16
Drug: Rituximab
Drug: Dexamethasone
Drug: Levofloxacin

First Posted Date: 2005-11-08

Last Posted Date: 2015-08-03

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 17

Registration Number: NCT00250718

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy